Yan Q. Xiong, Ph.D
Professor-in-Residence at the David Geffen School of Medicine at UCLA and an Investigator at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Dr. Xiong is a Professor-in-Residence at the David Geffen School of Medicine at UCLA and an Investigator at the Lundquist Institute at Harbor-UCLA Medical Center. She conducts research in bacterial infectious diseases focusing on the role of virulence factors, including bacterial global regulons, structural genes, and bacteriophages, in their ability to cause life-threatening infections and the development of resistance to antibiotics, particularly in Staphylococcus aureus. She is especially interested in how these virulence factors interact with the host in endovascular infections. Her long-term goal is to discover novel antimicrobial strategies for better preventing and treating serious infections caused by microbes, including multidrug-resistant organisms such as methicillin-resistant S. aureus.
Dr. Xiong obtained her medical degree from Tongji Medical University in China, followed by a Ph.D. in Microbiology from the University of Nantes, School of Medicine in France. She then completed a post-doctoral fellowship in infectious diseases at Harbor-UCLA Medical Center. She has published over 130 research articles in high impact, peer-reviewed journals and serves on editorial boards of leading journals. Dr. Xiong has maintained continuous funding from the NIH, American Heart Association and pharmaceutical drug companies for the last two decades.
Areas of Expertise
- Bacterial pathogenesis
- Mechanisms of antimicrobial agent resistance
- Clinically relevant animal models, including skin and soft tissue infections, bacteremia, endocarditis and pneumonia
Education
- MD, Tongji Medical School, Wuhan, China
- PhD, University of Nantes, School of Medicine, Nantes, France
Publications
Notable recent publications:
- Xiong YQ, Li Y, Goncheva MI, Elsayed AM, Zhu F, Li L, Abdelhady W, Flannagan RS, Yeaman MR, Bayer AS, Heinrichs DE. The purine biosynthesis repressor, PurR, contributes to vancomycin susceptibility of methicillin-resistant Staphylococcus aureus in experimental endocarditis. J Infect Dis. 2024 Jun 14;229(6):1648-57. PMID: 38297970.
- Li Y, Zhu F, Manna AC, Chen L, Jiang J, Hong J, Proctor R, Bayer AS, Cheung AL, Xiong YQ. Gp05, a prophage-encoded virulence factor, contributes to persistent methicillin-resistant Staphylococcus aureus endovascular infection. Microbiol Spectr. 2023 Aug 17;11(4):E0060023. PMID:37358448. PMCID:PMC10434118.
- Li L, Li Y, Zhu F, Cheung AL, Wang G, Bai G, Proctor RA, Yeaman MR, Bayer AS, Xiong YQ. New mechanistic insights into purine biosynthesis with second messenger c-di-AMP in relation to biofilm-related persistent methicillin-resistant Staphylococcus aureus infections. mBio. 2021 Dec 21;12(6):e0208121. PMID: 34724823. PMCID:PMC8561390.
- Li L, Wang G, Li Y, Francois P, Bayer AS, Chen L, Seidl K, Cheung AL, Xiong YQ. Impact of the novel prophage φSA169 on persistent methicillin-resistant Staphylococcus aureus endovascular infection. mSystmes. 2020 June 30;5(3):e00178-20. PMID: 32606024. PMCID:PMC7329321
A list of publications can be found here
© 2024 Lundquist. All rights reserved